AAAAAA

   
Results: 1-13 |
Results: 13
Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C
Authors: Propper, DJ McDonald, AC Man, A Thavasu, P Balkwill, F Braybrooke, JP Caponigro, F Graf, P Dutreix, C Blackie, R Kaye, SB Ganesan, TS Talbot, DC Harris, AL Twelves, C
Citation: Dj. Propper et al., Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C, J CL ONCOL, 19(5), 2001, pp. 1485-1492
A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis
Authors: Braybrooke, JP O'Byrne, KJ Propper, DJ Blann, A Saunders, M Dobbs, N Han, C Woodhull, J Mitchell, K Crew, J Smith, K Stephens, R Ganesan, TS Talbot, DC Harris, AL
Citation: Jp. Braybrooke et al., A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis, CLIN CANC R, 6(12), 2000, pp. 4697-4704
Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine
Authors: Braybrooke, JP Vallis, KA Houlbrook, S Rockett, H Ellmen, J Anttila, M Ganesan, TS Harris, AL Talbot, DC
Citation: Jp. Braybrooke et al., Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine, CANC CHEMOT, 46(1), 2000, pp. 27-34
Evaluation of the alkaline comet assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifen
Authors: Braybrooke, JP Houlbrook, S Crawley, JE Propper, DJ O'Byrne, KJ Stratford, IJ Harris, AL Shuker, DEG Talbot, DC
Citation: Jp. Braybrooke et al., Evaluation of the alkaline comet assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifen, CANC CHEMOT, 45(2), 2000, pp. 111-119
The RAD51 family member, RAD51L3, is a DNA-stimulated ATPase that forms a complex with XRCC2
Authors: Braybrooke, JP Spink, KG Thacker, J Hickson, ID
Citation: Jp. Braybrooke et al., The RAD51 family member, RAD51L3, is a DNA-stimulated ATPase that forms a complex with XRCC2, J BIOL CHEM, 275(37), 2000, pp. 29100-29106
Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid andinterferon alpha
Authors: Braybrooke, JP Propper, DJ O'Byrne, KJ Koukourakis, MI Patterson, AV Houlbrook, S Love, SD Varcoe, S Taylor, M Ganesan, TS Talbot, DC Harris, AL
Citation: Jp. Braybrooke et al., Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid andinterferon alpha, BR J CANC, 83(2), 2000, pp. 219-224
Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine
Authors: Propper, DJ Braybrooke, JP Levitt, NC O'Byrne, KO Christodoulos, K Han, C Talbot, DC Ganesan, TS Harris, AL
Citation: Dj. Propper et al., Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine, BR J CANC, 82(11), 2000, pp. 1759-1763
Phase II study of the oxygen saturation curve left shifting agent BW12C incombination with the hypoxia activated drug mitomycin C in advanced colorectal cancer
Authors: Propper, DJ Levitt, NC O'Byrne, K Braybrooke, JP Talbot, DC Ganesan, TS Thompson, CH Rajagopalan, B Littlewood, TJ Dixon, RM Harris, AL
Citation: Dj. Propper et al., Phase II study of the oxygen saturation curve left shifting agent BW12C incombination with the hypoxia activated drug mitomycin C in advanced colorectal cancer, BR J CANC, 82(11), 2000, pp. 1776-1782
Phase I study of the novel cyclic AMP (cAMP) analogue 8-chloro-cAMP in patients with cancer: Toxicity, hormonal, and immunological effects
Authors: Propper, DJ Saunders, MP Salisbury, AJ Long, L O'Byrne, KJ Braybrooke, JP Dowsett, M Taylor, M Talbot, DC Ganesan, TS Harris, AL
Citation: Dj. Propper et al., Phase I study of the novel cyclic AMP (cAMP) analogue 8-chloro-cAMP in patients with cancer: Toxicity, hormonal, and immunological effects, CLIN CANC R, 5(7), 1999, pp. 1682-1689
Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions
Authors: Macaulay, VM O'Byrne, KJ Saunders, MP Braybrooke, JP Long, L Gleeson, F Mason, CS Harris, AL Brown, P Talbot, DC
Citation: Vm. Macaulay et al., Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions, CLIN CANC R, 5(3), 1999, pp. 513-520
Phase I trial of the selective mitochondrial toxin MKT 077 in chemo-resistant solid tumours
Authors: Propper, DJ Braybrooke, JP Taylor, DJ Lodi, R Styles, P Cramer, JA Collins, WCJ Levitt, NC Talbot, DC Ganesan, TS Harris, AL
Citation: Dj. Propper et al., Phase I trial of the selective mitochondrial toxin MKT 077 in chemo-resistant solid tumours, ANN ONCOL, 10(8), 1999, pp. 923-927
A phase II study of the modulation of 5-fluorouracil and folinic acid withhigh-dose infusional hydroxyurea in metastatic colorectal carcinoma
Authors: O'Byrne, KJ Philip, PA Propper, DJ Braybrooke, JP Saunders, MP Bates, NP Taylor, MA Madigan, D Ganesan, TS Talbot, DC Harris, AL
Citation: Kj. O'Byrne et al., A phase II study of the modulation of 5-fluorouracil and folinic acid withhigh-dose infusional hydroxyurea in metastatic colorectal carcinoma, ANN ONCOL, 10(8), 1999, pp. 981-983
Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer
Authors: O'Byrne, KJ Dobbs, N Propper, DJ Braybrooke, JP Koukourakis, MI Mitchell, K Woodhull, J Talbot, DC Schally, AV Harris, AL
Citation: Kj. O'Byrne et al., Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer, BR J CANC, 79(9-10), 1999, pp. 1413-1418
Risultati: 1-13 |